Targeted p63 isoform switch corrects dominant mutations in AEC syndrome without disrupting epidermal homeostasis
The transcription factor p63 is a master regulator of stratified epithelial development, and its disruption causes severe congenital defects affecting the skin, limbs, and craniofacial structures in both humans and mice. Among p63-related disorders, Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate (AEC) syndrome is caused by dominant mutations primarily affecting the Sterile Alpha Motif (SAM) domain and the Transactivation Inhibitory Domain (TID) of the TP63 gene, which are unique to the p63 isoform. These mutations promote protein aggregation and transcriptional dysregulation, ultimately leading to debilitating skin erosions, suggesting that isoform-specific strategies could be therapeutically relevant. To explore a therapeutic strategy based on isoform switching, we generated a conditional mouse model with deletion of exon 13, resulting in replacement of p63 by the shorter p63{beta} isoform, which is expressed in the skin at lower levels. Although we found that p63 is required for limb and palate development, p63{beta} proved sufficient to support epidermal formation, postnatal skin homeostasis, and wound healing. At the molecular level, the switch from p63 to p63{beta} preserved chromatin binding and global transcriptional programs in keratinocytes. We next used genome editing to delete exon 13 in human primary keratinocytes, inducing a switch from p63 to p63{beta}. This isoform switch maintained normal proliferation and global gene expression. Importantly, p63{beta} expression in AEC patient-derived keratinocytes rescued protein aggregation, restored mechanical integrity, and normalized epidermal gene expression. Together, these findings demonstrate that p63{beta} can functionally compensate for p63 in the skin and establish and indicate that isoform switching could offer a new treatment option for AEC syndrome.